Perspective Therapeutics (CATX) Stock Forecast & Price Target

Compare

1,382 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CATX Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Perspective

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CATX Stock 12 Month Forecast

Average Price Target

$13.33

▲(254.52%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Perspective Therapeutics in the last 3 months. The average price target is $13.33 with a high forecast of $18.00 and a low forecast of $6.00. The average price target represents a 254.52% change from the last price of $3.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.39,3.590769230769231,4.791538461538462,5.992307692307692,7.193076923076923,8.393846153846154,9.594615384615386,10.795384615384616,11.996153846153847,13.196923076923078,14.397692307692308,15.598461538461539,16.79923076923077,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.39,3.2315384615384617,4.073076923076923,4.914615384615384,5.756153846153846,6.5976923076923075,7.439230769230768,8.28076923076923,9.122307692307691,9.963846153846154,10.805384615384614,11.646923076923077,12.488461538461538,{"y":13.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.39,2.667692307692308,2.9453846153846155,3.223076923076923,3.500769230769231,3.7784615384615385,4.056153846153846,4.333846153846154,4.611538461538462,4.889230769230769,5.1669230769230765,5.444615384615385,5.722307692307693,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.8,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$13.33

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Justin WalshJonesTrading

JonesTrading

$18

Buy

378.72%

Upside

Reiterated

06/25/25

Buy Rating for Perspective Therapeutics: Clinical Advancements and Strategic Developments Drive Positive Outlook

Nicole GerminoTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Perspective Therapeutics (NYSE MKT: CATX) and PTC Therapeutics (NASDAQ: PTCT)

David NierengartenWedbush

Wedbush

$11

Buy

192.55%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (NASDAQ: SKYE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Perspective Therapeutics (NYSE MKT: CATX)

Yuan ZhiB.Riley Financial

B.Riley Financial

$9→$12

Buy

219.15%

Upside

Reiterated

06/23/25

Perspective Therapeutics price target raised to $12 from $9 at B. RileyPerspective Therapeutics price target raised to $12 from $9 at B. Riley

Jeff JonesOppenheimer

Oppenheimer

$15

Buy

298.94%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Perspective Therapeutics (NYSE MKT: CATX) and Codexis (NASDAQ: CDXS)

Louise ChenScotiabank

Scotiabank

$15

Buy

298.94%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Ocular Therapeutix (NASDAQ: OCUL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Dennis KennedyLifeSci Capital

LifeSci Capital

$17

Buy

352.13%

Upside

Reiterated

06/22/25

Optimistic Buy Rating for Perspective Therapeutics Driven by Strategic Developments and Promising Clinical Data

Leonid TimashevRBC Capital

RBC Capital

$15→$16

Buy

325.53%

Upside

Reiterated

06/03/25

Perspective Therapeutics (CATX) Gets a Buy from RBC Capital

Alec StranahanBank of America Securities

Bank of America Securities

Hold

59.57%

Upside

Reiterated

06/02/25

Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$10

Buy

165.96%

Upside

Reiterated

05/19/25

Optimistic Buy Rating for Perspective Therapeutics Amid Financial Stability and Promising Clinical Developments

Kemp DolliverBrookline Capital Markets

Brookline Capital Markets

$11

Buy

192.55%

Upside

Initiated

03/10/25

Perspective Therapeutics initiated with a Buy at BrooklinePerspective Therapeutics initiated with a Buy at Brookline

Christopher LiuLucid Capital

Lucid Capital

$15→$20

Buy

431.91%

Upside

Reiterated

01/27/25

Perspective Therapeutics Inc (CATX) PT Raised to $20 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Perspective Therapeutics Inc (NYSE: CATX) to $20.00 (from $15.00) while maintaining a Buy rating.

David K. LaiUBS

UBS

$20

Buy

431.91%

Upside

Initiated

10/24/24

Perspective Therapeutics initiated with a Buy at UBSPerspective Therapeutics initiated with a Buy at UBS

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Justin WalshJonesTrading

JonesTrading

$18

Buy

378.72%

Upside

Reiterated

06/25/25

Buy Rating for Perspective Therapeutics: Clinical Advancements and Strategic Developments Drive Positive Outlook

Nicole GerminoTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Perspective Therapeutics (NYSE MKT: CATX) and PTC Therapeutics (NASDAQ: PTCT)

David NierengartenWedbush

Wedbush

$11

Buy

192.55%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (NASDAQ: SKYE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Perspective Therapeutics (NYSE MKT: CATX)

Yuan ZhiB.Riley Financial

B.Riley Financial

$9→$12

Buy

219.15%

Upside

Reiterated

06/23/25

Perspective Therapeutics price target raised to $12 from $9 at B. RileyPerspective Therapeutics price target raised to $12 from $9 at B. Riley

Jeff JonesOppenheimer

Oppenheimer

$15

Buy

298.94%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Perspective Therapeutics (NYSE MKT: CATX) and Codexis (NASDAQ: CDXS)

Louise ChenScotiabank

Scotiabank

$15

Buy

298.94%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Ocular Therapeutix (NASDAQ: OCUL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Dennis KennedyLifeSci Capital

LifeSci Capital

$17

Buy

352.13%

Upside

Reiterated

06/22/25

Optimistic Buy Rating for Perspective Therapeutics Driven by Strategic Developments and Promising Clinical Data

Leonid TimashevRBC Capital

RBC Capital

$15→$16

Buy

325.53%

Upside

Reiterated

06/03/25

Perspective Therapeutics (CATX) Gets a Buy from RBC Capital

Alec StranahanBank of America Securities

Bank of America Securities

Hold

59.57%

Upside

Reiterated

06/02/25

Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$10

Buy

165.96%

Upside

Reiterated

05/19/25

Optimistic Buy Rating for Perspective Therapeutics Amid Financial Stability and Promising Clinical Developments

Kemp DolliverBrookline Capital Markets

Brookline Capital Markets

$11

Buy

192.55%

Upside

Initiated

03/10/25

Perspective Therapeutics initiated with a Buy at BrooklinePerspective Therapeutics initiated with a Buy at Brookline

Christopher LiuLucid Capital

Lucid Capital

$15→$20

Buy

431.91%

Upside

Reiterated

01/27/25

David K. LaiUBS

UBS

$20

Buy

431.91%

Upside

Initiated

10/24/24

Perspective Therapeutics initiated with a Buy at UBSPerspective Therapeutics initiated with a Buy at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Perspective Therapeutics

1 Month

xxx

Success Rate

9/13 ratings generated profit

Average Return

+13.83%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +13.83% per trade.

3 Months

xxx

Success Rate

8/13 ratings generated profit

Average Return

+42.65%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +42.65% per trade.

1 Year

Nicole GerminoTruist Financial

Success Rate

4/7 ratings generated profit

Average Return

+12.10%

reiterated a buy rating 6 days ago

Copying Nicole Germino's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +12.10% per trade.

2 Years

xxx

Success Rate

4/7 ratings generated profit

Average Return

+12.10%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +12.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CATX Analyst Recommendation Trends

Rating

Jan 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CATX has received 25 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CATX average Analyst price target in the past 3 months is 13.33.

Each month's total comprises the sum of three months' worth of ratings.

CATX Financial Forecast

CATX Earnings Forecast

Next quarter’s earnings estimate for CATX is -$0.29 with a range of -$0.35 to -$0.19. The previous quarter’s EPS was -$0.25. CATX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year CATX has Outperformed its overall industry.

CATX Sales Forecast

Next quarter’s sales forecast for CATX is $186.00K with a range of $0.00 to $400.00K. The previous quarter’s sales results were $342.00K. CATX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year CATX has Outperformed its overall industry.

CATX Stock Forecast FAQ

What is CATX’s average 12-month price target, according to analysts?

Based on analyst ratings, Perspective Therapeutics’s 12-month average price target is 13.33.

What is CATX’s upside potential, based on the analysts’ average price target?

Perspective Therapeutics has 254.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CATX a Buy, Sell or Hold?

Perspective Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Perspective Therapeutics’s price target?

The average price target for Perspective Therapeutics is 13.33. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $6.00. The average price target represents 254.52% Increase from the current price of $3.76.

What do analysts say about Perspective Therapeutics?

Perspective Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of CATX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Perspective Therapeutics (CATX) Stock Forecast & Price Target

CATX Analyst Ratings

CATX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Perspective Therapeutics

CATX Analyst Recommendation Trends

CATX Financial Forecast

CATX Earnings Forecast

CATX Sales Forecast

CATX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts